Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Ammonium Hydroxide | HCID 14923 | — |
| Reactant | Sodium hydride | HCID 24758 | — |
| Reactant | 1-(3-Isopropyl-1,2,4-oxadiazol-5-YL)piperidin-4-OL | HCID 21897744 | — |
| Reactant | 7-(2-Fluoro-4-methanesulfonyl-phenyl)-4-methanesulfonyl-thieno[3,2-d]pyrimidine | HCID 68299280 | — |
| Solvent | Dimethylformamide | HCID 6228 | — |
| Product | GPR119 agonist 2 | HCID 86699298 | 59.7% |
Reaction Steps
1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-ol (30 mg) was dissolved in N,N-dimethylformamide (2 mL) and cooled to an internal temperature of 0° C. Then, NaH (9 mg) was slowly added thereto and stirred for 30 min. 7-(2-fluoro-4-methanesulfonyl-phenyl)-4-methanesulfonyl-thieno[3,2-d]pyrimidine (50 mg) synthesized in Preparation Example 2 was slowly added thereto and heated to room temperature, followed by stirring for 2 hours. Then, the reaction mixture was mixed with a saturated solution of ammonium hydroxide, and extracted twice with ethyl acetate. The organic layer thus obtained was washed with water, dried over anhydrous magnesium sulfate, and concentrated under reduced pressure to obtain a foamy residue. The residue was crystallized in the presence of diethyl ether to obtain the title compound (40 mg) as a whitish solid.
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US08853213B2 |
|---|
| Source dataset | uspto-grants-2014_10 |
|---|
| ORD ID | ord-a6374645a9fd4d26a7e8ae902fa7a44a |
|---|
| Source note | uspto-grants-2014_10 |
|---|